Callio Therapeutics
Callio Therapeutics develops dual-payload antibody-drug conjugates (ADCs) for people with cancer, including patients with tumors that have developed resistance to existing therapies. Its platform pairs synergistic drug payloads and uses a proprietary linker to design targeted treatments intended to overcome resistance and deliver more durable responses.
Facts
- HQ
- Seattle, WA, USA
- Sectors
- Biotechnology Research
- Founded
- 2025
- Employees
- 24
- Stage
- Series A
Is this your organization? Claim it
Hexagon Bio Secures $62M Series C to Advance HEX-360 HER2 ADC into Phase 1 Trials, Targeting H1 2027
Hexagon Bio raised $62 million in a Series C to fund a Phase 1 trial of HEX-360, a HER2-targeting antibody-drug conjugate using a novel translation-inhibitor payload designed to overcome resistance seen with existing ADC payloads; the trial is planned to begin enrolling in H1 2027.
People
See all 8-
Jerome Boyd-Kirkup Co-Founder
-
Piers Ingram Co-Founder
-
Chris Hassig Executive, Chief Scientific Officer